Nora Adriana Hernández-Cuevas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nora Adriana Hernández-Cuevas has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Andrea Marín-Cervera
Laboratorio de Parasitología, Centro de Investigaciones Regionales ‘Dr. Hideyo Noguchi’, Universidad Autónoma de Yucatán, Mérida, México
1 shared publicationEric Dumonteil
Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne and Infectious Disease Research Center, Tulane University, New Orleans, LA, USA
1 shared publication- Glendy M. Polanco-Hernández
Laboratorio de Biología Celular, Centro de Investigaciones Regionales “DR. Hideyo Noguchi”, Universidad Autónoma de Yucatán, Av. Itzaes No. 490 x 59 A, Merida 97000, Mexico
1 shared publication - Julio César Torres-Romero
Laboratorio de Bioquímica y Genética Molecular, Facultad de Química, Universidad Autónoma de Yucatán, Mérida, México
1 shared publication - Karla Yolanda Acosta-Viana
Laboratorio de Biología Celular, Centro de Investigaciones Regionales “Dr. Hideyo Noguchi” Universidad Autónoma de Yucatán Merida Mexico
1 shared publication - Luis P. López-López
Laboratorio de Biología Celular, Centro de Investigaciones Regionales “DR. Hideyo Noguchi”, Universidad Autónoma de Yucatán, Av. Itzaes No. 490 x 59 A, Merida 97000, Mexico
1 shared publication
Latest Publications
- Open Access
- 26 August 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (3) , 40
Activity of β-Caryophyllene Oxide and Benznidazole Mixture Against Trypanosoma cruzi and In Silico Prediction of Anti-Trypanocidal Interaction
Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, affecting approximately 6–7 million people worldwide. The current treatment lacks efficacy in the chronic phase of the disease. This study aims to determine the in vitro synergistic activity of concomitant therapy (benznidazole with β-caryophyllene oxide) against Trypanosoma cruzi, assess its cytotoxicity, and propose the mechanism of this synergism through in silico analysis. The tested concentrations of the treatment demonstrated hemocompatibility (80% cell viability). Additionally, synergistic activity against the parasite was confirmed, reducing epimastigote viability by up to 80%. In this work, in silico analysis revealed that β-caryophyllene oxide also binds to the T. cruzi ABC channel in regions localized to amino acids 108–271 and 399–558, suggesting this interaction could inhibit it. This treatment emerges as a promising candidate for Chagas disease therapy. It lacks cytotoxic and hemolytic activity while exhibiting synergism against the parasite, such as through the inhibition of ABC channels, as suggested in silico.
- 26 August 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (3) , 40
Open AccessActivity of β-Caryophyllene Oxide and Benznidazole Mixture Against Trypanosoma cruzi and In Silico Prediction of Anti-Trypanocidal Interaction
Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, affecting approximately 6–7 million people worldwide. The current treatment lacks efficacy in the chronic phase of the disease. This study aims to determine the in vitro synergistic activity of concomitant therapy (benznidazole with β-caryophyllene oxide) against Trypanosoma cruzi, assess its cytotoxicity, and propose the mechanism of this synergism through in silico analysis. The tested concentrations of the treatment demonstrated hemocompatibility (80% cell viability). Additionally, synergistic activity against the parasite was confirmed, reducing epimastigote viability by up to 80%. In this work, in silico analysis revealed that β-caryophyllene oxide also binds to the T. cruzi ABC channel in regions localized to amino acids 108–271 and 399–558, suggesting this interaction could inhibit it. This treatment emerges as a promising candidate for Chagas disease therapy. It lacks cytotoxic and hemolytic activity while exhibiting synergism against the parasite, such as through the inhibition of ABC channels, as suggested in silico.
- 24 May 2021
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 148 (9) , 1067-1073
Fibronectin degradation as biomarker for Trypanosoma cruzi infection and treatment monitoring in mice
Biomarkers (coming from host or parasite) to monitor Chagas disease (CD) progression as well as the therapeutic response in chronic CD are critically needed, since seronegativization, which may be considered the best indicator of therapeutic cure, takes several years to be observed in adults. Several molecules have been suggested as biomarkers for CD, however, they have to be validated. Taking advantage of mouse models of Trypanosoma cruzi infection, we investigated changes in the degradation profile of fibronectin in plasma. The degradation profile of fibronectin was different in the acute phase compared to the chronic phase of the infection. Fibronectin fragments of approximately 150, 100, 40 and 30 kDa were identified. Furthermore, those degradation profiles correlated with acute parasitaemia as well as with cardiac parasite burden and tissue damage during the infection. The usefulness of fibronectin degradation as a biomarker for therapeutic response following drug treatment and immunotherapeutic vaccination also was evaluated and a decreased fibronectin degradation profile was observed upon benznidazole or a vaccine candidate treatment.
- 24 May 2021
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 148 (9) , 1067-1073
Fibronectin degradation as biomarker for Trypanosoma cruzi infection and treatment monitoring in mice
Biomarkers (coming from host or parasite) to monitor Chagas disease (CD) progression as well as the therapeutic response in chronic CD are critically needed, since seronegativization, which may be considered the best indicator of therapeutic cure, takes several years to be observed in adults. Several molecules have been suggested as biomarkers for CD, however, they have to be validated. Taking advantage of mouse models of Trypanosoma cruzi infection, we investigated changes in the degradation profile of fibronectin in plasma. The degradation profile of fibronectin was different in the acute phase compared to the chronic phase of the infection. Fibronectin fragments of approximately 150, 100, 40 and 30 kDa were identified. Furthermore, those degradation profiles correlated with acute parasitaemia as well as with cardiac parasite burden and tissue damage during the infection. The usefulness of fibronectin degradation as a biomarker for therapeutic response following drug treatment and immunotherapeutic vaccination also was evaluated and a decreased fibronectin degradation profile was observed upon benznidazole or a vaccine candidate treatment.